Tags

Type your tag names separated by a space and hit enter

Audit of early experience with inhaled nitric oxide in New Zealand neonatal intensive care units.
N Z Med J. 1998 Dec 11; 111(1079):474-7.NZ

Abstract

AIMS

To audit the use of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn in New Zealand neonatal intensive care units.

METHODS

Prospective data collection on all infants treated with inhaled nitric oxide in neonatal intensive care units in the 20-month period from first use to December 1995. Data included perinatal factors, principal diagnosis, echocardiogram results, ventilation details and response to nitric oxide, adverse reactions and outcome.

RESULTS

Twenty-eight infants received nitric oxide in three centres, all bar one being 36 weeks or more gestation. Overall survival was 68%. Thirteen infants (46%) responded to nitric oxide treatment, 12 (92%) surviving. Seven (47%) of non-responders survived. Infants with primary pulmonary hypertension or meconium aspiration syndrome had 90% survival and more often responded to nitric oxide than infants with congenital diaphragmatic hernia (40% survival) or pulmonary hypoplasia (no survivors). No serious complications of treatment were recorded.

CONCLUSIONS

Inhalational nitric oxide was not universally successful treatment for pulmonary hypertension of the newborn but was likely to have been life-saving in a proportion of cases. Future studies may allow better case selection. Ongoing audit of this new treatment is warranted.

Authors+Show Affiliations

Darlow B
Department of Paediatrics, Christchurch School of Medicine. bdarlow@chmeds.ac.nz
Kempthorne P
No affiliation info available
Knight D
No affiliation info available
Wong M
No affiliation info available

MeSH

Administration, InhalationBronchodilator AgentsHernia, DiaphragmaticHernias, Diaphragmatic, CongenitalHumansHypertension, PulmonaryInfant, NewbornIntensive Care Units, NeonatalLung DiseasesMeconium Aspiration SyndromeNew ZealandNitric OxideProspective StudiesSurvival AnalysisTreatment OutcomeVasodilator Agents

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9972202

Citation

Darlow, B, et al. "Audit of Early Experience With Inhaled Nitric Oxide in New Zealand Neonatal Intensive Care Units." The New Zealand Medical Journal, vol. 111, no. 1079, 1998, pp. 474-7.
Darlow B, Kempthorne P, Knight D, et al. Audit of early experience with inhaled nitric oxide in New Zealand neonatal intensive care units. N Z Med J. 1998;111(1079):474-7.
Darlow, B., Kempthorne, P., Knight, D., & Wong, M. (1998). Audit of early experience with inhaled nitric oxide in New Zealand neonatal intensive care units. The New Zealand Medical Journal, 111(1079), 474-7.
Darlow B, et al. Audit of Early Experience With Inhaled Nitric Oxide in New Zealand Neonatal Intensive Care Units. N Z Med J. 1998 Dec 11;111(1079):474-7. PubMed PMID: 9972202.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Audit of early experience with inhaled nitric oxide in New Zealand neonatal intensive care units. AU - Darlow,B, AU - Kempthorne,P, AU - Knight,D, AU - Wong,M, PY - 1999/2/11/pubmed PY - 1999/2/11/medline PY - 1999/2/11/entrez SP - 474 EP - 7 JF - The New Zealand medical journal JO - N Z Med J VL - 111 IS - 1079 N2 - AIMS: To audit the use of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of the newborn in New Zealand neonatal intensive care units. METHODS: Prospective data collection on all infants treated with inhaled nitric oxide in neonatal intensive care units in the 20-month period from first use to December 1995. Data included perinatal factors, principal diagnosis, echocardiogram results, ventilation details and response to nitric oxide, adverse reactions and outcome. RESULTS: Twenty-eight infants received nitric oxide in three centres, all bar one being 36 weeks or more gestation. Overall survival was 68%. Thirteen infants (46%) responded to nitric oxide treatment, 12 (92%) surviving. Seven (47%) of non-responders survived. Infants with primary pulmonary hypertension or meconium aspiration syndrome had 90% survival and more often responded to nitric oxide than infants with congenital diaphragmatic hernia (40% survival) or pulmonary hypoplasia (no survivors). No serious complications of treatment were recorded. CONCLUSIONS: Inhalational nitric oxide was not universally successful treatment for pulmonary hypertension of the newborn but was likely to have been life-saving in a proportion of cases. Future studies may allow better case selection. Ongoing audit of this new treatment is warranted. SN - 0028-8446 UR - https://www.unboundmedicine.com/medline/citation/9972202/Audit_of_early_experience_with_inhaled_nitric_oxide_in_New_Zealand_neonatal_intensive_care_units_ L2 - https://medlineplus.gov/lungdiseases.html DB - PRIME DP - Unbound Medicine ER -